Diabetes and cancer: A comprehensive review

Abudawood, Manal

doi:10.4103/jrms.jrms_242_19

Cited by 113 publications

(101 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Diabetes is emerging as one of the most prevalent human aliments next to cardiovascular diseases and is the sixth leading cause of death worldwide [1] . A number of studies have related diabetes to cancer risk; furthermore, growing evidences suggested an abnormal glucose homeostasis as an independent risk factor for the development of specific neoplasms [2] .…”

Section: Introductionmentioning

confidence: 99%

Relationship between Diabetes Mellitus and Clinicopathological Stages of Breast Cancer at Diagnosis

Ali

Mohamed

Khattab

et al. 2020

Benha Medical Journal

View full text Add to dashboard Cite

Diabetes is a risk factor for development of specific neoplasms, including breast cancer. Women with type-2 diabetes mellitus (T2DM) are at increased risk for developing breast cancer. Breast cancer subtypes have been extensively studied, but few studies have examined whether diabetic women present with more advanced breast cancer stages. Aim of study: evaluate whether T2DM has effect on clinicopathological stages of breast cancer at diagnosis. Subjects and methods: 102 breast cancer women were studied, 51 had T2DM and 51 were non-diabetic. Clinical assessment, BMI, FBS, 2-hPPBS, HbA1c level, total cholesterol, triglyceride, C-peptide, breast mammography, and body imaging and scanning were performed. Biopsy samples from breast tissues were reviewed; histologic morphology and grades were determined. Hormone receptor status (ER, PR, HER2) was determined. Clinical stages of breast cancer were determined based on TNM staging system. Results: BMI was significantly higher in type-2 diabetic breast cancer women compared to nondiabetic. Type-2 diabetic breast cancer women had more invasive pathologic subtypes and advanced stages of breast cancer compared to those who were non-diabetic. Breast cancer women with invasive duct carcinoma had significantly higher BMI (32.0±6.1kg/m 2), FBS (130.3±30.4mg/dL), 2-hPPBS (221.6±72.5mg/dL), HbA1c (7.8±2.2%), cholesterol (202.2±39.9mg/dL), and triglyceride (154.9±16.1mg/dL) compared to those with ductal carcinoma in situ. Conclusion and recommendation: breast cancer in type-2 diabetic women is often diagnosed at advanced stages and being of more aggressive pathologic subtype. Whether proper control of diabetic status has effect on progression of breast cancer needs further studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Relationship between Diabetes Mellitus and Clinicopathological Stages of Breast Cancer at Diagnosis

Ali

Mohamed

Khattab

et al. 2020

Benha Medical Journal

View full text Add to dashboard Cite

show abstract

“…Extensive studies have been conducted to unravel the links between diabetes and cancer. 22 Several mechanisms, including abnormality of glucose homeostasis and insulin resistance, have been suggested to involve as risk factors in the development of cancer survival in diabetes mellitus patients. 1,23 Tumor suppressor p53 has associated with having a significant impact in respect of diabetes and cancer progression.…”

Section: Discussionmentioning

confidence: 99%

<p>Sera Anti-P53 Antibody Provides New Information Which Explains the Link Between Diabetes and Cancer</p>

Sauriasari

Sekar

Aisyah

et al. 2020

DMSO

View full text Add to dashboard Cite

Introduction: Abnormalities in glucose metabolism in diabetic patients may lead to an increased risk of certain cancers. Epidemiological studies and meta-analysis have shown that factors such as gender, age, obesity, and insulin resistance are related to cancer incidence. The anti-p53 antibody is a known cancer marker due to tumor-associated p53 accumulation. Many studies have aimed to unravel the link between diabetes and cancer. Here, we aimed to elucidate the impact of diabetes on malignancies by analyzing anti-p53 antibody in sera of type 2 diabetes mellitus (T2DM) patients. Materials and Methods: We conducted an observational study with a cross-sectional design. A total of 149 subjects comprised of 78 T2DM patients (32 with cancer risk and 46 subjects without cancer risk), 51 T2DM patients with cancer, and 20 healthy subjects as controls from multisites. The anti-p53 antibody was measured by enzyme-linked immunosorbent assay, while HbA1c was measured using the NGSP standardized method. Results: We observed an 8.3-fold (p<0.05) increase of anti-p53 antibody in the sera of T2DM patients and a 24-fold increase (p<0.001) in T2DM patients with cancer compared to healthy subjects. The anti-p53 antibodies significantly increased almost three times (p<0.05) in T2DM patients with cancer (0.72 U/mL±0.20) compared to T2DM patients (0.25 U/mL±0.05). Meanwhile, this antibody was almost undetectable in healthy subjects as a control group (0.03 U/ mL±0.03). The anti-p53 antibody level was higher in T2DM with cancer risk patients. However, we did not find a significant difference for it in T2DM without cancer risk patients (0.19 U/mL±0.03) and T2DM with cancer risk patients (0.29 U/mL±0.08). Multivariate regression analysis showed that T2DM with cancer was the only one independent factor (beta=0.218, p=0.019) that could predict the increase of anti-p53 antibody, controlled by age, gender, BMI, DM duration, and HbA1c. Conclusion: Our results showed that anti-p53 antibody almost not detected in healthy subjects, but 8.3-fold increase in the sera of T2DM patients and 24-fold increase in T2DM patients with cancer. Therefore, this biomarker provides new information which explains the link between diabetes and cancer.

show abstract

“…Diabetes Mellitus (DM) is a heterogeneous disorder characterized by a loss in glucose homeostasis and insulin resistance [131]. DM is a CV risk factor, and hyperglycemia is associated with chronic endothelium inflammation and endothelial dysfunction [132][133][134][135][136][137].…”

Section: Diabetes Mellitusmentioning

confidence: 99%

Use of Human Umbilical Vein Endothelial Cells (HUVEC) as a Model to Study Cardiovascular Disease: A Review

et al. 2020

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of death worldwide, and extensive research has been performed to understand this disease better, using various experimental models. The endothelium plays a crucial role in the development of CVD, since it is an interface between bloodstream components, such as monocytes and platelets, and other arterial wall components. Human umbilical vein endothelial cell (HUVEC) isolation from umbilical cord was first described in 1973. To date, this model is still widely used because of the high HUVEC isolation success rate, and because HUVEC are an excellent model to study a broad array of diseases, including cardiovascular and metabolic diseases. We here review the history of HUVEC isolation, the HUVEC model over time, HUVEC culture characteristics and conditions, advantages and disadvantages of this model and finally, its applications in the area of cardiovascular diseases.

show abstract

Diabetes and cancer: A comprehensive review

Cited by 113 publications

References 73 publications

Relationship between Diabetes Mellitus and Clinicopathological Stages of Breast Cancer at Diagnosis

Relationship between Diabetes Mellitus and Clinicopathological Stages of Breast Cancer at Diagnosis

<p>Sera Anti-P53 Antibody Provides New Information Which Explains the Link Between Diabetes and Cancer</p>

Use of Human Umbilical Vein Endothelial Cells (HUVEC) as a Model to Study Cardiovascular Disease: A Review

Contact Info

Product

Resources

About